MedPath

Eye & ENT Hospital of Fudan University

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

96

Active:3
Completed:16

Trial Phases

6 Phases

Early Phase 1:6
Phase 1:2
Phase 2:8
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (78 trials with phase data)• Click on a phase to view related trials

Not Applicable
52 (66.7%)
Phase 2
8 (10.3%)
Early Phase 1
6 (7.7%)
Phase 4
6 (7.7%)
Phase 3
4 (5.1%)
Phase 1
2 (2.6%)

Perceptual Evaluation and Rehabilitation System Development for Congenital Hearing Loss

Not Applicable
Not yet recruiting
Conditions
Gene Therapy
Congenital Hearing Loss
Speech Perception
Rehabilitation
Reliability and Validity
First Posted Date
2025-06-17
Last Posted Date
2025-07-01
Lead Sponsor
Eye & ENT Hospital of Fudan University
Target Recruit Count
210
Registration Number
NCT07024524
Locations
🇨🇳

Eye & ENT Hospital of Fudan University, Shanghai, China

Study on the Surgical Strategy of Corneal Endothelial Protection for Hard Nuclear Cataract Patients

Not Applicable
Completed
Conditions
Hard Nuclear Cataract
Phacoemulsification Cataract Surgery
Endothelial Cell Density Loss
Central Corneal Thickness
First Posted Date
2025-05-28
Last Posted Date
2025-05-28
Lead Sponsor
Eye & ENT Hospital of Fudan University
Target Recruit Count
207
Registration Number
NCT06991374
Locations
🇨🇳

Eye and ENT Hospital, Fudan University, Shanghai, Shanghai, China

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

Early Phase 1
Recruiting
Conditions
Retinoblastoma
Retinoblastoma, Recurrent
Interventions
Other: Collection of aqueous humor
Other: Electroretinogram
First Posted Date
2025-05-15
Last Posted Date
2025-05-15
Lead Sponsor
Eye & ENT Hospital of Fudan University
Target Recruit Count
10
Registration Number
NCT06972602
Locations
🇨🇳

Fudan Eye & ENT Hospital, Shanghai, China

Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts

Recruiting
Conditions
Cataract
Fuchs Endothelial Corneal Dystrophy
First Posted Date
2025-05-11
Last Posted Date
2025-06-17
Lead Sponsor
Eye & ENT Hospital of Fudan University
Target Recruit Count
120
Registration Number
NCT06966167
Locations
🇨🇳

Eye and ENT hospital of Fudan University, Shanghai, Shanghai, China

CG-101 Eye Drops in the Treatment of Dry Eye Syndrome

Early Phase 1
Recruiting
Conditions
Dry Eye
Interventions
Drug: CG101 high dose + artificial tear
Drug: placebo + artificial tear
Drug: CG101 low dose + artificial tear
First Posted Date
2025-01-27
Last Posted Date
2025-01-27
Lead Sponsor
Eye & ENT Hospital of Fudan University
Target Recruit Count
30
Registration Number
NCT06792903
Locations
🇨🇳

Eye & ENT hospital of Fudan University, Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 19
  • Next

News

GenEditBio Doses First Patient in World's First In Vivo CRISPR Trial for TGFBI Corneal Dystrophy

GenEditBio has dosed the first patient in a groundbreaking investigator-initiated trial of GEB-101, marking the world's first clinical study of an in vivo CRISPR-Cas ribonucleoprotein-based genome editing therapy for TGFBI corneal dystrophy.

Bilateral Gene Therapy Restores Hearing in Both Ears for Children with Inherited Deafness

Five children with DFNB9 inherited deafness gained hearing in both ears after receiving bilateral gene therapy targeting OTOF gene mutations in a world-first clinical trial.

© Copyright 2025. All Rights Reserved by MedPath